anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A biological magnetic fluid includes a magnetic colloidal disperse phase distributed throughout a liquid dispersion medium. The disperse phase may be made up of magnetic particles coated with cross-linked biologically compatible polymers. The biologically compatible polymers may be connected by way of covalent linkages to biologically active macromolecules. This may be accomplished by covalently linking immunoglobulin to the biologically compatible polymers and then attaching antibodies with predefined specificity to the immunoglobulin. These antibodies may target the magnetic particles on desired cells, for a variety of medical applications. The magnetic particles may be made up of magnetite cores with cobalt or cobalt and boron coatings. In addition magnetic particles may be made of icobalt and boron with the boron being in sufficient concentration to enable radiation activation. The magnetic colloid may be formed by incorporating the biologically compatible polymer into the colloid as the colloid is being formed by reducing a magnetic metallic salt. The colloid is advantageously produced in a multi-stage process in order to achieve very uniform particle sizes. The magnetic colloid may also be made by forming a biologically incompatible magnetic colloid, and slowly adding the colloid to a vigorous I biologically compatible polymer. These biological magnetic fluids are useful, for example, in separating cancerous cells from normal cells in bone marrow transplants.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to physiotherapy, exercise therapy, neurology, pulmonology, medical rehabilitation, and can be used in early recovery of ischemic stroke (IS) in the presence of accompanying chronic respiratory system disorders outside exacerbation. That is ensured by a complex exposure involving drug-induced, physiotherapeutic exposure and therapeutic exercise (TE). Drug-induced exposure includes daily nebuliser inhalations of broncho- and mucolytics and daily intramuscular injections of cortexin 10 mg, 10 days, . Physiotherapeutic exposure includes common gas-air dry carbonic baths (DCB) with temperature of 32–34 °C with flow rate of 20 l/min in training mode: starting from carbon dioxide concentration of 0.7 g/l, bringing in the last procedure up to 1.4 g/l, with exposure ranging from 12 minutes on the first procedure to 5 minutes at the last, only 7 procedures every second day for 2 weeks. TE includes a mechanotherapy, which is carried out in the form of functional training aimed at improving movements in joints of hands, on the Reo Go simulator for 20 minutes daily, 10 days, and in the form of a functional training walking skill – on C-mill simulator 5 days week for 20 minutes, total – 10 days. Also, the daily massage exposure for 10 days, including hydro-massage in the form of vortex baths for limbs, wherein the vortex baths are carried out at water temperature of 37–38 °C for 10 minutes for each limb. It is combined with manual massage of the collar zone for 15 minutes. That is followed by Strelnikov's respiratory gymnastics or exercises with respiratory breathing resistance, daily, for 20 minutes after physiotherapeutic procedures, before mechanotherapy is performed on the simulators.EFFECT: method provides prolonged remission of chronic obstructive bronchopulmonary pathology and absence of repeated strokes up to 2 years.1 cl
OBJECTIVES: Metabolic Syndrome (MetS) has been established as a significant factor in the pathogenesis of numerous chronic inflammatory conditions. However, its role in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is unknown. This study aims to investigate the association between MetS, its components, and the risk of postoperative recurrence in Chinese patients with CRSwNP.
METHODS: A retrospective cohort study was conducted on CRSwNP patients who underwent endoscopic sinus surgery in our hospital. Patients were divided into MetS and non-MetS groups, and the clinical characteristics and recurrence rates were compared. All CRSwNP patients were followed up for more than 2-years and further categorized into non-recurrent and recurrent groups. Binary logistic regression analyses were performed to examine the effects of MetS and its components on the risk of postoperative recurrence.
RESULTS: A total of 555 CRSwNP patients were enrolled in the present study, 157 patients were included in the MetS group and 398 patients were categorized into the non-MetS group. The recurrence rate in the MetS group was significantly higher compared to the non-MetS group (p < 0.05). The rate of MetS, overweight or obesity, hyperglycemia and dyslipidemia were higher in the recurrent group in comparison with the non-recurrent group (p < 0.05). Multivariate logistic regression analysis suggested that MetS, overweight or obesity, hyperglycemia, dyslipidemia, and accompanying allergic rhinitis were associated with the risk of postoperative recurrence of CRSwNP (p < 0.05). Moreover, adjusted and unadjusted regression models showed that MetS was an independent risk factor for postoperative recurrence of CRSwNP, and the risk increased with more components of MetS included (p < 0.05).
CONCLUSION: Our findings revealed that MetS independently increased the risk of postoperative recurrence in patients with CRSwNP, with the risk escalating as the number of MetS components increased. Moreover, accompanying allergic rhinitis was also demonstrated to be a potential risk factor for CRSwNP recurrence.
LEVEL OF EVIDENCE: Level 4.
PULMICORT RESPULES, will often help control asthma symptoms with less suppression of HPA function than therapeutically equivalent oral doses of prednisone. Since individual sensitivity to effects on cortisol production exists, physicians should consider this information when prescribing PULMICORT RESPULES. Because of the possibility of systemic absorption of inhaled corticosteroids, patients treated with PULMICORT RESPULES should be observed carefully for any evidence of systemic corticosteroid effects. Particular care should be taken in observing patients post-operatively or during periods of stress for evidence of inadequate adrenal response. It is possible that systemic corticosteroid effects such as hypercorticism, and adrenal suppression (including adrenal crisis) may appear in a small number of patients, particularly when budesonide is administered at higher than recommended doses over prolonged periods of time. If such effects occur, the dosage of PULMICORT RESPULES should be reduced slowly, consistent with accepted procedures for tapering of systemic corticosteroids and for management of asthma.
Rhein, a component derived from rhubarb, has been proven to possess anti-inflammatory properties. Here, we show that rhein mitigates obesity by promoting adipose tissue thermogenesis in diet-induced obese mice. We construct a macrophage-adipocyte co-culture system and demonstrate that rhein promotes adipocyte thermogenesis through inhibiting NLRP3 inflammasome activation in macrophages. Moreover, clues from acetylome analysis identify SIRT2 as a potential drug target of rhein. We further verify that rhein directly interacts with SIRT2 and inhibits NLRP3 inflammasome activation in a SIRT2-dependent way. Myeloid knockdown of SIRT2 abrogates adipose tissue thermogenesis and metabolic benefits in obese mice induced by rhein. Together, our findings elucidate that rhein inhibits NLRP3 inflammasome activation in macrophages by regulating SIRT2, and thus promotes white adipose tissue thermogenesis during obesity. These findings uncover the molecular mechanism underlying the anti-inflammatory and anti-obesity effects of rhein, and suggest that rhein may become a potential drug for treating obesity.
BACKGROUND: Urinary albumin-creatinine ratio (UACR) and estimated glomerular filtration rates (eGFR) help predict worsening diabetic kidney disease (DKD) but have their limitations. Soluble tumor necrosis factor receptor type 1 (sTNFR1) is a biomarker of DKD. The predictive abilities of sTNFR1 and UACR plus eGFR have not been compared.
METHODS: This prospective cohort study included patients with type 2 diabetes (T2D) to identify the risk factors of worsening DKD. Renal events were defined as > 30 % loss in eGFR based on consecutive tests after 6 months. The associations of sTNFR1, UACR, and eGFR levels and the risks of renal events were tested using a Cox regression model and the area under the curve (AUC) was compared between sTNFR1 levels and UACR plus eGFR using receiver-operating characteristic (ROC) analysis. The accuracy of stratification was evaluated using Kaplan-Meier analysis.
RESULTS: Levels of sTNFR1 and UACR were associated with risks of > 30 % decline in eGFR after adjusting for relevant factors. The association between sTNFR1 levels and renal outcomes was independent of UACR and eGFR at baseline. The AUC of sTNFR1 level was comparable with that of combined UACR and eGFR (0.73 vs. 0.71, respectively, p = 0.72) and the results persisted for quartile groups of sTNFR1 and risk categories of Kidney Disease: Improving Global Outcomes (KDIGO) (0.70 vs. 0.71, respectively, p = 0.84). Both stratifications by sTNFR1 levels and KDIGO were accurate.
CONCLUSION: sTNFR1 could be an alternative marker for identifying patients with diabetes at risk of declining renal function.
An important task for the visual system is to identify and segregate objects from background. Figure-ground illusions, such as Edgar Rubin's bistable 'vase-faces illusion'1, make the point clearly: we see either a central vase or lateral faces, alternating spontaneously, but never both images simultaneously. The border is perceptually assigned to either faces or vase, which become figure, the other shapeless background2. The stochastic alternation between figure and ground probably reflects mutual inhibitory processes that ensure a single perceptual outcome3. Which shape dominates perception depends on many factors, such as size, symmetry, convexity, enclosure, and so on, as well as attention and intention4. Here we show that the assignment of the visual border can be strongly influenced by auditory input, far more than is possible by voluntary intention. VIDEO ABSTRACT.
The present invention is directed to compositions comprising nanoparticulate heterocyclic amide derivative and preferably zafirlukast nanoparticles, also collectively referred to as "active ingredient," having improved solubility in water. The nanoparticles of the composition have an effective average particle size of less than about 2,000 nm, and are useful in the treatment of asthma.  The invention also relates to a multiparticulate modified release composition comprising the active ingredient that in operation delivers the drug in a pulsed or bimodal manner for the treatment of asthma. The controlled release composition comprises an immediate release component and a modified release component. The immediate release component comprises a first population of heterocyclic amide derivative, and preferably zafirlukast particles, and the modified release component comprises a second population of heterocyclic amide derivative, and preferably zafirlukast nanoparticles, and a controlled release component, wherein the combination of the immediate release and modified release components in operation delivers the active ingredient in a pulsed or bimodal manner. The heterocyclic amide derivative can be released from the multiparticulate particles in an erosable, diffusion or osmotic controlled release system.
Produced by Air Liquefaction

OXYGEN 2 18033 (12/14) 

WARNING: For emergency use only when administered by properly trained personnel for oxygen deficiency and resuscitation. For all other medical applications, Rx only. Uninterrupted use of high concentrations of oxygen over a long duration, without monitoring its effect on oxygen content of arterial blood, may be harmful. Do not attempt to use on patients who have stopped breathing unless used in conjunction with resuscitative equipment. DANGER: MAY CAUSE OR INTENSIFY FIRE; OXIDIZER. CONTAINS GAS UNDER PRESSURE; MAY EXPLODE IF HEATED. Do not handle until all safety precautions have been read and understood. Keep and store away from clothing and other combustible materials. Keep valves and fittings free from grease and oil. Use and store only outdoors or in a well-ventilated place. In case of fire: Stop leak if safe to do so. Use a backflow preventive device in the piping. Use only with equipment of compatible materials of construction and rated for cylinder pressure. Use only with equipment cleaned for oxygen service. Open valve slowly. Close valve after each use and when empty. Protect from sunlight when ambient temperature exceeds 52°C (125° F). Read and follow the Safety Data Sheet (SDS) before use. CAS 7782-44-7 DO NOT REMOVE THIS PRODUCT LABEL.

VOLUNTEER WELDING SUPPLY

815 5 TH AVE SOUTH • NASHVILLE, TN 37203 

615-256-5658
The aging population in Poland poses significant socioeconomic and health challenges, particularly regarding malnutrition among seniors. This study examines the impact of place of residence on the nutritional status and related health outcomes of older adults. Data were collected from 338 community-dwelling seniors and those in long-term care facilities. The results indicate that long-term care residents exhibited significantly higher frailty and depression levels and poorer nutritional status, functional fitness, gait, and balance compared to those in communities. Self-reported quality of life did not differ significantly between groups. Regardless of residence, having a family correlated with better nutritional status, quality of life, and functional fitness and lower frailty and depression levels. Malnutrition was significantly associated with reduced functional fitness across all residences, and well-nourished individuals in care facilities had lower functional fitness than those who were at home. Community-dwelling residents had significantly lower frailty levels, with frailty negatively correlating with nutritional status. Normal nutritional status was linked to higher balance and gait scores, indicating a lower fall risk, with the risk further reduced for those living in community settings. Additionally, normal nutritional status correlated with lower depression levels and higher quality of life, with malnourished individuals experiencing better quality of life in community-dwelling settings. These findings underscore the critical role of residence and family support in elderly nutrition and health outcomes.
This study used data from a randomized controlled trial on the efficacy of hypnosis with analgesic suggestions relative to hypnosis with nonspecific suggestions to explore two areas. The first was the immediate effects of each hypnosis session and their relevance to the treatment induced change in pain intensity. The second was the identification of variables associated with the beneficial effects of hypnosis treatment in the form of reducing pain intensity and pain quality. The predictive value of the initial treatment response, hypnotizability, and the dichotomous variable of pain medication use were examined. Both interventions resulted in similar significant reductions in pain intensity after each session, but without a cumulative effect. The initial response correlated positively and moderately with pain intensity decreases induced by the complete hypnosis treatment. There was only a weak association between hypnotizability and pain quality improvement. Only participants not taking pain medications achieved a meaningful reduction in pain outcomes. Each hypnosis session results in an immediate reduction in chronic nociplastic pain intensity, and a fruitful first session may be a positive signal to continue therapy. Even patients with low hypnotizability can obtain beneficial outcomes. Pain medication use may become a new predictor in hypnosis research, as significant decreases in pain intensity and pain quality occurred only in the absence of pharmacotherapy. However, the results of this study require confirmation in further research with longer treatment periods.
The invention relates to the technical field of biological medicine. In particular, the invention relates to a fomes fomentarius compound extract, a preparation method and an application thereof. The fomes fomentarius compound extract is prepared from the following components according to a weight ratio of 1-10 parts of fomes fomentarius:1-9 parts of phellinus pini:1 part of ganoderma lucidum; the extraction method of the compound extract comprises: preparing a fomes fomentarius compound, mixing, crushing, adding pure water, performing water extraction and alcohol precipitation to obtain a supernatant, performing reduced pressure concentration, and performing vacuum drying of the concentrate to obtain the product. The content of triterpene and triterpene saponin in the fomes fomentarius compound extract of the invention is not less than 5.5%. The extract not only has significant in-vivo and in-vitro antineoplastic efficacy, but also has no obvious acute toxicity; the maximum tolerance dose for mice is 0.2 g (equivalent to 4.58 g of crude drugs), which is 327 times of human oral dosage. The extract can be prepared into compound preparation when mixed with pharmaceutically acceptable carriers, and the compound preparation can be oral liquid, injection, suspension, pills, tablets, capsules, powder, granules, or drop pills.
PCT No. PCT/US94/10215 Sec. 371 Date May 23, 1997 Sec. 102(e) Date May 23, 1997 PCT Filed Sep. 12, 1994 PCT Pub. No. WO96/08558 PCT Pub. Date Mar. 21, 1996The effects of suppressing c-fos oncogene expression on drug or radiation resistant mammalian cells are described. A2780S human ovarian carcinoma cells with resistance to actinomycin D were isolated and the resultant A2780AD cells exhibited the MDR phenotype. A hammerhead ribozyme designed to cleave fos RNA cloned into the pMAMneo plasmid was transfected into A2780AD cells. Induction of the ribozyme resulted in decreased expression of c-fos, followed by that of mdr-1, c-jun, and p53. Reversal of the MDR phenotype by the anti-mdr ribozyme occurred one-fourth as rapidly as that induced by the anti-fos ribozyme. These studies demonstrate the primacy of the c-fos oncogene in maintaining the resistant phenotype in human cancer cells. Thus, down regulation of fos/jun will make resistant cancer cells more sensitive to conventional treatment, i.e., cancer chemotherapeutic agents and/or radiation.
In a study in nonhuman primates, RECOTHROM Thrombin topical (Recombinant) was applied directly to a liver wound with an absorbable gelatin sponge, USP. In a second study, RECOTHROM was administered subcutaneously once weekly for four weeks to nonhuman primates following repeat doses of 5405 units/m2. In both studies, RECOTHROM had no effect on clinical signs, serum chemistry, coagulation parameters, or histopathology; only normal postsurgical findings were observed. No animals developed anti-RECOTHROM product antibodies in either study.

RECOTHROM was found to be non-irritating when instilled in the eyes (200 units) or applied to normal or abraded skin of rabbits (up to 1000 units/site).

To evaluate RECOTHROM inhibition and clearance from the bloodstream, radiolabeled RECOTHROM was administered intravenously or subcutaneously to nonhuman primates and applied with an absorbable gelatin sponge, USP, in a rabbit hepatic wound model. RECOTHROM did not circulate in the blood as free, active molecule, but was rapidly inactivated (<5 minutes) after formation of complexes with endogenous inhibitors (e.g., antithrombin III); these complexes were cleared by the liver. RECOTHROM applied with an absorbable gelatin sponge, USP, was shown to decrease time to hemostasis (TTH) when compared to saline in a rabbit hepatic wound model and rat heminephrectomy model. RECOTHROM also reduced TTH when directly applied in a porcine partial-thickness excisional skin-wound model as compared to saline control (or no treatment).

RECOTHROM applied with a gauze sponge decreased TTH in a concentration-dependent manner in both the rabbit and rat models. Concentrations of RECOTHROM >1000 units/mL were no different than 1000 units/mL while the effect of RECOTHROM diluted to a concentration of 100 units/mL on TTH was indistinguishable from placebo.

The performance of RECOTHROM mixed with gelatin matrix (FLOSEAL NT Hemostatic Matrix, 5mL) was compared to FLOSEAL Hemostatic Matrix, 5mL (human plasma-derived thrombin mixed with gelatin matrix) in a blinded nonclinical study using a heparinized porcine liver punch model of moderate to severe bleeding. The analysis demonstrated that the performance of RECOTHROM mixed with gelatin matrix was non-inferior to human plasma-derived thrombin mixed with gelatin matrix.
PROBLEM TO BE SOLVED: To inactivate a virus regardless of the presence or absence of an envelope while maintaining the biological activity of a therapeutically useful protein such as protein constituent ingredients of the serum by using acridine or an acridine derivative. SOLUTION: A virus is inactivated by using acridine or an acridine derivative, preferably 3,6-diamino-10-methylacridinium chloride, etc. When benzalkonium chloride is used together with the acridine or the acridine derivative, inactivating effects are preferably synergistically improved. The inactivation is concretely preferably carried out by adding the acridine or the acridine derivative at 0.01-0.001 g/L concentration and the benzalkonium chloride at 0.05-0.01 g/L concentration to a protein solution such as the total blood, serum, plasma or milk and performing incubation at pH 3-10 or 5-9 and 20-40 deg.C or 25-37 deg.C for 2-5 hr. The acridine and benzalkonium chloride can be removed from the protein solution by, e.g. dialysis, etc.
The present invention relates to a novel inhibitor of histamine release, designed HRIF which is believed to represent a promising therapeutic agent for treatment of basophil and mast cell dependent disorders, including allergic diseases. This inhibitor is a human cytokine that antagonizes a human histamine releasing cytokine(s) designated HRF. HRIF has a molecular weight of about 8,000 to 10,000 daltons as determined by gel exclusion chromatography and has also been purified by ion exchange chromatography. HRIF is stable when heated at 60°C for one hour, when frozen and thawed four times, and when treated with neuraminidase. Treatment with trypsin or chymotrypsin substantially destroys the activity of HRIF. The present invention includes compositions comprising substantially purified HRIF as well as methods for HRIF production and use. The invention also includes HRIF-producing cell lines and methods for producing such cell lines.
Participants with Parkinsonian Syndrome (PS), Essential Tremor (ET), and Healthy Volunteers (HV) received a single dose of DaTSCAN™ ioflupane (123I) injection. Single photon emission computed tomography (SPECT) imaging was performed between 3 to 6 hours post-injection and lasted approximately 20 minutes to 1 hour.